Tuberculosis during TNF-α inhibitor therapy, despite screening

Regina W Hofland; Steven F T Thijsen; Marc A M T Verhagen; Yolande Schenk; Ailko W J Bossink

doi:10.1136/thoraxjnl-2012-202974

Tuberculosis during TNF-α inhibitor therapy, despite screening

Regina W Hofland, Steven F T Thijsen, Marc A M T Verhagen, Yolande Schenk, Ailko W J Bossink

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.

Original language	English
Pages (from-to)	1079-80
Number of pages	2
Journal	Thorax
Volume	68
Issue number	11
DOIs	https://doi.org/10.1136/thoraxjnl-2012-202974
Publication status	Published - Nov 2013

Keywords

Adult
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Female
Humans
Immunocompromised Host
Inflammatory Bowel Diseases
Infliximab
Latent Tuberculosis
Male
Middle Aged
Tuberculin Test
Tuberculosis, Pulmonary
Tumor Necrosis Factor-alpha
Case Reports
Journal Article

Access to Document

10.1136/thoraxjnl-2012-202974

Cite this

@article{bc537e24cee44376aee459cbd1df1425,

title = "Tuberculosis during TNF-α inhibitor therapy, despite screening",

abstract = "As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.",

keywords = "Adult, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Female, Humans, Immunocompromised Host, Inflammatory Bowel Diseases, Infliximab, Latent Tuberculosis, Male, Middle Aged, Tuberculin Test, Tuberculosis, Pulmonary, Tumor Necrosis Factor-alpha, Case Reports, Journal Article",

author = "Hofland, {Regina W} and Thijsen, {Steven F T} and Verhagen, {Marc A M T} and Yolande Schenk and Bossink, {Ailko W J}",

year = "2013",

month = nov,

doi = "10.1136/thoraxjnl-2012-202974",

language = "English",

volume = "68",

pages = "1079--80",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "11",

}

TY - JOUR

T1 - Tuberculosis during TNF-α inhibitor therapy, despite screening

AU - Hofland, Regina W

AU - Thijsen, Steven F T

AU - Verhagen, Marc A M T

AU - Schenk, Yolande

AU - Bossink, Ailko W J

PY - 2013/11

Y1 - 2013/11

N2 - As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.

AB - As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.

KW - Adult

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Antibodies, Monoclonal

KW - Female

KW - Humans

KW - Immunocompromised Host

KW - Inflammatory Bowel Diseases

KW - Infliximab

KW - Latent Tuberculosis

KW - Male

KW - Middle Aged

KW - Tuberculin Test

KW - Tuberculosis, Pulmonary

KW - Tumor Necrosis Factor-alpha

KW - Case Reports

KW - Journal Article

U2 - 10.1136/thoraxjnl-2012-202974

DO - 10.1136/thoraxjnl-2012-202974

M3 - Article

C2 - 23598710

SN - 0040-6376

VL - 68

SP - 1079

EP - 1080

JO - Thorax

JF - Thorax

IS - 11

ER -

Tuberculosis during TNF-α inhibitor therapy, despite screening

Abstract

Keywords

Access to Document

Fingerprint

Cite this